Haemonetics Corporation Reports First‑Quarter Fiscal 2027 Results and Advances in Vascular Closure Technology
Haemonetics Corporation (NYSE: HAE), a Boston‑based provider of automated blood‑processing systems, disclosed its first‑quarter fiscal 2027 financial results on August 6, 2026. The results cover the period ending June 27, 2026 and are now available on the company’s Investor Relations website at www.haemonetics.com .
The company will host a conference call and webcast for investors and analysts on the same day at 8:00 a.m. ET to discuss the results in detail. Registration is available through a link provided on the Investor Relations page.
Key Financial Highlights (First Quarter FY 2027)
| Metric | Value |
|---|---|
| Fiscal period | Q1 FY 2027 (ending 27 Jun 2026) |
| Release date | 6 Aug 2026 |
| Availability | Investor Relations website, www.haemonetics.com |
(Specific revenue, earnings, and cash‑flow figures are not provided in the release; the company’s market capitalization was $3.88 billion as of the close on 4 Aug 2026.)
Product‑Pipeline and Clinical Development Updates
VASCADE MVP® XL System – A new retrospective cohort study, the largest reported to date, demonstrates the safety and efficacy of Haemonetics’ VASCADE MVP® XL venous vascular closure system in large‑bore sheath electrophysiology procedures. The study was conducted at Emory University and supported by a grant from Haemonetics. The findings reinforce the system’s role in improving patient outcomes during high‑risk procedures.
Safety Data for Vascular Closure Device – Earlier in August, Haemonetics released additional safety data from a study focused on its vascular closure device. The data support the device’s safety profile, although specific metrics were not detailed in the press release.
Market Context
Share Performance – As of the market close on 4 Aug 2026, Haemonetics’ shares traded at $83.60, within a 52‑week range of $47.32 (low) to $88.59 (high). The company’s price‑earnings ratio stood at 41.06, indicating investor expectations of continued growth in earnings.
Industry Position – Haemonetics operates in the Health Care Equipment & Supplies sector, specializing in automated blood‑processing systems for surgical blood salvage, blood component collection, and plasma collection. Its global reach positions the company to capitalize on increasing demand for advanced perioperative blood management technologies.
Outlook
Haemonetics’ forthcoming conference call will provide deeper insights into the quarter’s financial performance, product pipeline progress, and strategic initiatives. Stakeholders can anticipate a discussion of how recent clinical evidence supports the company’s product positioning and its implications for revenue growth.
For further details, analysts and investors are encouraged to review the full financial release and supplemental presentation available on Haemonetics’ Investor Relations portal.
